Andreas Katopodis | CEO
Anaveon

Andreas Katopodis, CEO, Anaveon

Andreas is co-founded Anaveon in April 2018, and previously was the Director of Autoimmunity, Transplantation & Inflammation, Novartis Institutes of  Biomedical Research, Basel Big Pharma experience in the discovery and development of immunomodulating drugs (26 years) Extensive BD&L experience, supported and closed multiple deals between pharma and start-ups Faculty at the Georgia Institute of Technology (5 years)

Appearances:



World Immunotherapy Congress 2018, Day 1 @ 16:50

Next generation cancer immunotherapy using IL-2/antibody complexes

  • Present our re-direct strategy to increase the efficacy of IL-2 therapy and decrease toxicity
  • Antibody development and in vitro data
  • In vivo data in mice (and possibly monkeys)
  • Late pre-clinical development activities
last published: 17/Jul/18 15:35 GMT
last published: 17/Jul/18 15:35 GMT

back to speakers

Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates